Overview

The Gene Technology Act 2000 was enacted by the Australian Parliament to establish a regulatory framework for the development and use of genetically modified organisms (GMOs) in Australia. This Act was introduced to address the need for a structured approach to managing the risks associated with gene technology to ensure the protection of human health and the environment. The policy objective of the Act is to facilitate the safe development and use of gene technology while minimising potential risks. The Office of the Gene Technology Regulator, established under this Act, is responsible for assessing applications for the release of GMOs and determining whether such releases pose any significant risks. The Regulator seeks public consultation to inform its decision-making process, ensuring transparency and community engagement in regulatory outcomes.

Scope and Application

The proposed genetically modified wheat field trial is subject to the regulatory framework established under the Gene Technology Act 2000, which aims to safeguard human health and the environment by controlling the risks associated with gene technology. This Act applies to the entities involved in the genetic modification and proposed release of the GM wheat, including the Victorian Department of Primary Industries as the applicant and the Gene Technology Regulator who is assessing the licence application. The trial, confined to a specific geographic area near Horsham, Victoria, is subject to national regulations, with the Regulator holding jurisdiction over the application and its compliance with the legislative and risk management standards. The scope of the Act extends to all activities related to the genetically modified wheat, including its cultivation, evaluation, and containment, but excludes any commercialisation or incorporation into human food or animal feed. The application of the Act is further refined through subordinate instruments, such as the RARMP, which provides detailed conditions and risk management strategies for the proposed field trial.

Key Provisions

The main operative sections of the legislation, C2013G01217, involve the assessment and potential approval of a Licence Application DIR 122 for a genetically modified wheat field trial. Section 1 outlines the purpose of the trial, which is to evaluate the agronomic performance of genetically modified (GM) wheat under field conditions. This is to be conducted over two growing seasons from November 2013 to December 2015, near Horsham, Victoria, on a maximum area of 2 hectares per season. Importantly, Section 2 specifies that the GM wheat would not be permitted in human food or animal feed. The proposed trial is governed by a Risk Assessment and Risk Management Plan (RARMP), which has been prepared to assess the risks posed by the trial and to provide draft licence conditions to manage those risks. The obligations imposed by the legislation on the parties involved are multifaceted. The Victorian Department of Primary Industries, as the applicant, must submit a comprehensive application under Section 3, including the RARMP, to the Gene Technology Regulator. This application must detail the proposed trial, the potential environmental and health impacts, and the measures to mitigate any identified risks. The Regulator, under Section 4, is required to conduct a thorough assessment of the application, including reviewing the RARMP and any public submissions received. Additionally, under Section 5, the Regulator must consider the findings of the RARMP and determine whether the proposed trial poses negligible risk to human health and the environment. In terms of consequences for breach, the legislation does not explicitly outline specific offences or penalties within the text provided. However, under Australian law, unauthorised activities involving genetically modified organisms can lead to significant legal consequences. If the trial proceeds without proper authorisation or if it breaches the conditions set out in the licence, the applicants could face civil penalties, including fines, and criminal penalties, such as imprisonment. These penalties are governed by the relevant sections of the Gene Technology Act 2000 and could vary depending on the severity and nature of the breach. It is important to note that the Regulator’s decision to issue the licence is contingent upon the satisfactory completion of all requirements and the conclusion that the trial poses negligible risk, as per the RARMP.